Exabis Library
Welcome to the e-CCO Library!
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP43: Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRN
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cells
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM